Sections
You are here: Home > News
Press Contact

Kaspar Mossman

kaspar.mossman@ucsf.edu

(415) 514-9790

 

News

Current News

  • Genome sequenced for amoeba that flips into free-swimming cell

    Scientists have sequenced the genome of a weird, single-celled organism called Naegleria gruberi. The genome is teaching biologists about the transition from prokaryotes, which function just fine with all their proteins floating around in a soup, to eukaryotes, which neatly compartmentalize those proteins into nuclei and mitochondria. QB3's Dan Rokhsar is a coauthor of the research. (read more)

  • QB3's drug discovery center to collaborate with Genentech

    Under the terms of a $13 million partnership, Genentech will support the work of several researchers at the UCSF Small Molecule Discovery Center (SMDC), which is administered by the UCSF School of Pharmacy and located at QB3 on the UCSF Mission Bay campus. A research team at Genentech will work closely with UCSF to develop a drug candidate based on prior academic research conducted at the SMDC and discoveries at Genentech. (read more)

  • QB3 adds Zcube as limited partner in Mission Bay Capital Fund

    Mission Bay Capital, LLC, has added a new limited partner to its first venture fund, bolstering the fund’s ability to invest in promising bioscience companies emerging from the University of California. Zcube, Srl, the research corporate venture of Italian pharmaceutical leader Zambon Co., SpA, joined the Mission Bay Capital Fund with a $1 million investment. (read more)

  • Jay Keasling elected to National Academy of Engineering

    QB3's Jay Keasling, professor of biochemical engineering at UC Berkeley and director of the Physical Biosciences Division at LBNL, was one of six faculty at UC Berkeley recently elected to the National Academy of Engineering. Keasling was elected "for developing synthetic biology tools to engineer the antimalarial drug artemisinin." (read more)

  • DeRisi team wins $1 million Keck Award; will develop technology for vaccine designers

    A team led by QB3’s Joe DeRisi, PhD, UCSF professor of biochemistry and biophysics and HHMI Investigator, recently received a $1 million award from the W. M. Keck Foundation to develop technology that will aid researchers seeking to design a vaccine for malaria and other infectious diseases. (read more)